Alnylam Pharmaceuticals (ALNY) Reports Q4 Net Income

Alnylam Pharmaceuticals (ALNY) reported net income of $225 million in the fourth quarter ended December 31, 2025, a 12% increase from $201 million in the same period of 2024. The company generated revenue of $1.09 billion, up 18% year-over-year. EPS for the quarter was $1.16, up from $1.01 in Q4 2024. The results reflect continued growth in its RNAi-based therapies, with sales of its lead product, givosiran, contributing $490 million in the quarter.